Sulindac metabolites inhibit epidermal growth factor receptor activation and expression

Journal of Carcinogenesis

Volumn 4, Issue , 2005, Pages

  Pangburn, Heather A ^a,b   Kraus, Hanna ^a   Ahnen, Dennis J ^a,b,c   Rice, Pamela L ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SULINDAC SULFIDE; SULINDAC SULFONE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL GROWTH; CELL LYSATE; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; GENE ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOBLOTTING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 26844460663     PISSN: 14773163     EISSN: 14773163     Source Type: Journal    
DOI: 10.1186/1477-3163-4-16     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10-30.
2. Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1(1):11-21.
3. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94(4):252-66.
4. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ: Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2003, 2(9):885-92.
5. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res 2001, 61(4):1541-7.
6. Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ: Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res 2003, 63(3):616-20.
7. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997, 57(14):2909-15.
8. Rice PL, Beard KS, Driggers LJ, Ahnen DJ: Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res 2004, 64(22):8148-51.
9. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 1997, 94(2):657-62.
10. DuBois RN, Awad J, Morrow J, Roberts LJ 2nd, Bishop PR: Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994, 93(2):493-8.
11. Kokoska ER, Smith GS, Miller TA: Nonsteroidal anti-inflammatory drugs attenuate proliferation of colonic carcinoma cells by blocking epidermal growth factor-induced Ca++ mobilization. J Gastrointest Surg 2000, 4(2):150-61.
12. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM: Combinatorial chemoprevention of intestinal neoplasia. Nature Med 2000, 6:1024-1028.
13. Kokoska ER, Smith GS, Wolff AB, Deshpande Y, Miller TA: Nonsteroidal anti-inflammatory drugs attenuate epidermal growth factor-induced proliferation independent of prostaglandin synthesis inhibition. J Surg Res 1999, 84(2):186-92.
14. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T: Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999, 1438(1):120-30.
15. Winde G, Lugering N, Glodny B, Schmid KW, Muller O, Senninger N, Osswald H: Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. Cancer Lett 1998, 134(2):201-7.
16. Duke R, Cohen JJ: Morphological and biochemical assays of apoptosis. In Current Protocols in Immunology Edited by: K Coligan JE, AM, Margulies DJ, Shevach EM, Strober W. Wiley-Interscience: New York; 1992:3.17.1-3.17.16.
17. Lowry OHRN, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-275.
18. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M: Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005, 65(8):3003-10.
19. Messa C, Russo F, Caruso MG, Di Leo A: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998, 37(3):285-9.
20. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3):183-232.
21. Kirschbaum MH, Yarden Y: The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms. J Cell Biochem Suppl 2000, 34:52-60.
22. O'Dwyer PJ, Benson AB 3rd: Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002, 29(5 Suppl 14):10-7.
23. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988, 48(1):137-41.
24. Skibber J, Minsky BD, Hoff P: Cancer of the colon, in Cancer: Principles and Practice of Oncology. Edited by: HS DeVita VT, Rosenberg SA. Lippincott Williams & Wilkins: Philadelphia; 2001:1216-1270.
25. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71(8):2454-60.
26. Radinsky R: Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995, 14(4):323-38.
27. Jimeno A, Hidalgo M: Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol 2005, 53(3):179-92.
28. Jost M, Class R, Kari C, Jensen PJ, Rodeck U: A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J Invest Dermatol 1999, 112(4):443-9.
29. Kari C, Chan TO, Rocha de Quadros M, Rodeck U: Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003, 63(1):1-5.
30. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J: Involvement of p27KIP1 in G1 arrest mediated by an antiepidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12(7):1397-403.
31. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284(1):31-53.